EAST HANOVER, N.J. - Novartis announced on Nov. 17 that the U.S. Food and Drug Administration approved Cosentyx 150 mg for adults with polymyalgia rheumatica, making it the first anti-IL-17 biologic cleared for the inflammatory condition.
First Biologic Option Beyond Steroids
The approval covers adult patients who had an inadequate response to corticosteroids or cannot tolerate tapering off steroids, marking Cosentyx's 11th U.S. indication. Polymyalgia rheumatica causes severe pain and stiffness in the shoulders, neck, and hips and affects about 966,000 Americans. Doctors have long relied on steroids, even though up to 40% of patients relapse within their first year of treatment.
Phase III Trial Doubles Remission Rates
Regulators based the decision on the Phase III REPLENISH study conducted across 27 countries and published in the New England Journal of Medicine. Following a 24-week steroid taper, 40.5% of patients receiving Cosentyx 150 mg achieved sustained remission at Week 52, compared with 20.5% on placebo. "In the Phase III REPLENISH trial, secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment," said lead investigator Prof. John Stone.
Safety Profile and Global Reviews
Serious adverse events occurred in 15.9% of Cosentyx-treated patients versus 14.2% in the placebo group, consistent with the drug's established safety profile. The polymyalgia rheumatica indication is already approved in the European Union and remains under regulatory review in Japan.



